James Connell

Scientific Director - LifeArc

Scientific Director at LifeArc, one of the UK’s largest self-funding medical research organisations, with over 20 years’ research experience specialising in neuroscience, translational research, and drug discovery.

At LifeArc I am responsible for leading innovative and ambitious research programmes, to accelerate the development of disease modifying treatments for MND. This is part of LifeArc’s MND-Translational Challenge, a £50million investment in translational research where there is a high unmet patient need.

Previously I was Head of Translational Research at the not-for-profit, Alzheimer’s Research UK, leading the Dementia Consortium, an academic-industry alliance for target validation and early-stage drug discovery in neurodegenerative disease.

Research Associate at the University of Cambridge working on the hereditary motor neuron disorder spastic paraplegia.

Principal Scientist at Talisman Therapeutics working on drug discovery programmes using stem cell models of dementia.

PhD from the Institute of Psychiatry, King’s College London on the Mechanisms of tau induced neurodegeneration in Alzheimer’s disease and frontotemporal dementia (FTDP-17).